Bepreve (bepotastine) is filed as Ophthalmic Antihistamine. The sections below restate public label fields stored for this profile.
1 INDICATIONS AND USAGE BEPREVE ® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H 1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis. BEPREVE is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis. ( 1 )
12.1 Mechanism of Action Bepotastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.
4 CONTRAINDICATIONS BEPREVE is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients [see Adverse Reactions ( 6.2 )] . Hypersensitivity to any component of this product. ( 4 )
The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions which occurred in 2-5% of subjects were eye irritation, headache, and nasopharyngitis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
2 DOSAGE AND ADMINISTRATION Instill one drop of BEPREVE into the affected eye(s) twice a day. Remove contact lenses prior to instillation of BEPREVE. • Instill one drop into the affected eye(s) twice a day. ( 2 ) • Remove contact lenses prior to instillation of BEPREVE. ( 2 )
According to its FDA label, Bepreve (bepotastine) is approved for: 1 INDICATIONS AND USAGE BEPREVE ® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H 1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis. BEPREVE is a histamine H1 receptor antagonist indicated f… For medical advice, please talk to your prescriber or pharmacist.
Bepreve (bepotastine) belongs to the Ophthalmic Antihistamine class of medications.
The FDA label lists Bepreve (bepotastine) as: 3 DOSAGE FORMS AND STRENGTHS Ophthalmic solution containing bepotastine besilate 15 mg/mL (1.5%). Ophthalmic solution containing bepotastine besilate, 15 mg/mL (1.5%). ( 3 ); ophthalmic route. Available strengths and packaging vary by manufacturer.
Yes. A generic version of Bepreve (bepotastine) is available in the U.S. Ask your pharmacist about substitution.
Our ingest of the FDA label for Bepreve (bepotastine) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
Public CMS NADAC pricing for Bepreve (bepotastine) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.
The FDA Enforcement Report does not show an active/ongoing recall for Bepreve (bepotastine) in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA record lists the approval date for Bepreve (bepotastine) as 2009-09-08.
The FDA label lists Bausch & Lomb Incorporated as a labeler/manufacturer of Bepreve (bepotastine). Multiple firms may market generics of the same molecule.
The FDA label states: "Bepotastine Besilate Ophthalmic Solution, 1.5% is a sterile, clear colorless to pale yellow solution practically free from particles. Each mL of bepotastine besilate ophthalmic solution contains 15 mg bepotastine besilat…" Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…